This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Research Report for AT&T, Goldman Sachs & Sanofi
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Goldman Sachs (GS) and Sanofi (SNY).
Biotech Stock Roundup: REGN Cuts Praluent Price, OREX to File for Bankruptcy
by Zacks Equity Research
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Key pharma franchises in a bustling pipeline have shares looking attractive again at 17X and 15% EPS growth
3 Biotech Stocks With Rising Earnings Estimates Post Q4
by Zacks Equity Research
The biotech industry performed reasonably well in Q4. Hence, it is a good idea to select stocks from the sector which saw positive estimate revisions post Q4 earnings release.
Regeneron and Sanofi Announce Positive Data on Praluent
by Zacks Equity Research
Regeneron (REGN) & Sanofi's Praluent achieves the primary endpoint in the ODYSSEY OUTCOMES trial as the drug reduces the overall risk of MACE by 15%.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
Biotech Stock Round Up: Regeneron Submits sBLA, Biogen to Withdraw Zinbryta
by Zacks Equity Research
The biotech sector was in focus last week with these stories - FDA's acceptance of Regeneron's Dupixent's application for asthma, Biogen and partner AbbVie's decision to withdraw multiple sclerosis drug among others.
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
by Zacks Equity Research
Zacks Industry Outlook Highlights: Sanofi, Celgene, Bioverativ, Juno and Merck
FDA Accepts Regeneron/Sanofi's Dupixent sBLA for Asthma
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) and partner Sanofi announced that the FDA has accepted the companies' sBLA for Dupixent for asthma with a target date of Oct 20, 2018.
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio
by Zacks Equity Research
Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
Biotech Crushing the Market: Best ETFs & Stocks YTD
by Sweta Killa
The recent developments are fueling growth in the biotech companies, leading to a rally in their share prices and impressive levels of momentum in biotech ETFs.
Emergent (EBS) Q4 Earnings Beat Estimates, 2018 View Solid
by Zacks Equity Research
Emergent's (EBS) earnings and revenues beat estimates in Q4. The top line also improves year over year on higher product sales.
BioMarin (BMRN) Q4 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
BioMarin (BMRN) reports wider-than-expected loss in the fourth quarter of 2017 but beat estimates for sales on higher product revenues.
Merck to Buy Australian Firm to Boost Immunotherapy Pipeline
by Zacks Equity Research
Merck (MRK) to buy Australian oncolytic immunotherapies maker Viralytics Limited to strengthen its presence in the fast growing immuno-oncology market.
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ExxonMobil, Caterpillar, Union Pacific, Alexion and Sanofi
Top Research Reports for ExxonMobil, Caterpillar & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including ExxonMobil (XOM), Caterpillar (CAT) and Union Pacific (UNP).
Foreign Stock Roundup: TOT, STO & GSK Earnings Impress, BP & SNY Disappoint
by Swarup Gupta
Global stocks were weighed down by massive losses and heightened volatility on Wall Street last week.
Alnylam's (ALNY) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alnylam Pharmaceuticals (ALNY) reports narrower-than-expected loss and beats sales estimates in the fourth quarter of 2017.
Regeneron (REGN) Q4 Earnings & Revenues Top, Eylea Sales Grow
by Zacks Equity Research
Regeneron (REGN) fourth-quarter results were encouraging as the company topped both earnings and sales estimates on the back of Eylea sales.
Biogen Halts Tysabri Development in Stroke as Study Fails
by Zacks Equity Research
Biogen's Tysabri (natalizumab) falters in a phase IIb study, evaluating it for acute ischemic stroke (AIS) indication.
Sanofi (SNY) Q4 Earnings Lag on Weak Diabetes/Vaccines Sales
by Zacks Equity Research
Sanofi misses estimates for both earnings and sales in the fourth quarter hurt by continued weakness in the Diabetes franchise and lower vaccine sales. Sanofi looks to return to growth in 2018.
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?
by Zacks Equity Research
Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.
Will Regeneron (REGN) Disappoint Investors in Q4 Earnings?
by Zacks Equity Research
With a mixed track record, we expect investor focus on Regeneron's (REGN) Eylea sales and uptake of Dupixent when it reports Q4 results.
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, Seattle Genetics, AbbVie, Celgene and Vertex
Merck (MRK) Beats on Q4 Earnings, Lags Sales, Guides for '18
by Zacks Equity Research
Merck (MRK) beats estimates for earnings but misses the same for sales in Q4. Sales of Keytruda remain strong in the quarter.